Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Jill Henrich Sells 1,000 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Jill Henrich sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $11.20, for a total value of $11,200.00. Following the completion of the transaction, the executive vice president now owns 19,378 shares of the company’s stock, valued at $217,033.60. This represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Atara Biotherapeutics Price Performance

Shares of ATRA stock traded down $0.31 on Wednesday, reaching $10.68. 108,460 shares of the company were exchanged, compared to its average volume of 107,467. Atara Biotherapeutics, Inc. has a one year low of $6.50 and a one year high of $39.50. The company has a 50-day moving average of $9.09 and a 200-day moving average of $10.10. The company has a market cap of $61.52 million, a price-to-earnings ratio of -0.41 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same period in the prior year, the firm posted ($16.50) earnings per share. As a group, sell-side analysts predict that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ATRA. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and dropped their target price for the company from $25.00 to $18.00 in a report on Friday, August 16th. Canaccord Genuity Group raised their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $16.67.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of large investors have recently modified their holdings of the company. Delap Wealth Advisory LLC bought a new position in Atara Biotherapeutics during the first quarter valued at approximately $29,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics during the second quarter valued at approximately $53,000. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics during the second quarter valued at $79,000. State Street Corp boosted its stake in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. 70.90% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.